NCT06498648 2026-03-19
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Recruiting
Clinical Trials
14 trialsNCT04031677 2026-03-18
STRASS2
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT06088290 2026-03-11
SaLuDo
PharmaMar
Phase 3 Recruiting
NCT03016819 2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3 Recruiting
NCT06308419 2026-02-25
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07432932 2026-02-25
PANTHR-S
Royal Marsden NHS Foundation Trust
Recruiting
NCT04554914 2026-02-20
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Pierre Fabre Medicament
Phase 2 Recruiting
NCT04055220 2026-02-17
REGOSTA
Centre Leon Berard
Phase NA Recruiting
NCT04925089 2026-02-17
Localized Leiomyosarcoma Biomarker Protocol
University of Michigan Rogel Cancer Center
Recruiting
NCT07125183 2026-02-05
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
University of Colorado, Denver
Phase 2 Recruiting
NCT07169344 2026-01-28
PROSARC-1
Oslo University Hospital
Phase 2 Recruiting
NCT07173972 2026-01-28
PROSARC-2
Oslo University Hospital
Phase 2 Recruiting
NCT06571734 2026-01-09
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma
Northwestern University
Phase 2 Recruiting
NCT05653388 2025-12-26
Metastatic Leiomyosarcoma Biomarker Protocol
University of Michigan Rogel Cancer Center
Recruiting